TITLE

Drug and Medical Device Interactions: Stent Thrombosis and Personalizing Clopidogrel Therapy

AUTHOR(S)
Giusti, Betti; Gori, Anna Maria; Marcucci, Rossella; Saracini, Claudia; Vestrini, Anna; Abbate, Rosanna
PUB. DATE
June 2010
SOURCE
Current Pharmacogenomics & Personalized Medicine;2010, Vol. 8 Issue 2, p124
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Antiplatelet therapy with aspirin and clopidogrel, aimed to inhibit platelet function and reactivity, is the recommended standard of care for reducing the occurrence of cardiovascular events in patients with acute coronary syndromes undergoing percutaneous coronary intervention with stent implantation. However, major adverse cardiovascular events including the severe complication of stent thrombosis occur in patients taking dual antiplatelet therapy. Clopidogrel requires intestinal absorption and hepatic conversion to active metabolite by several cytochrome P450 isoenzymes, among which the CYP2C19 plays a pivotal role; then, the active metabolite inhibits ADP-stimulated platelet activation by irreversibly binding to the P2Y12 receptor. Several factors interacting with each other are involved in determining the variability of individual response to clopidogrel. Nongenetic factors include chronic persistent factors (e.g., age, diabetes) and acute phase transient factors (e.g., inflammation). Among the numerous genetic variants investigated, recently, the loss-offunction CYP2C19*2 polymorphism has been associated with a decreased metabolization of clopidogrel, poor antiaggregant effect, and increased cardiovascular events. In high risk vascular patients, who experience percutaneous coronary intervention with stent implantation, the CYP2C19*2 polymorphism is a strong predictor of the adverse cardiovascular events and particularly stent thrombosis. Ongoing and future prospective studies evaluating if an antiplatelet treatment tailored on individual characteristics of patients - genetic variants, platelet phenotype, drug-drug interactions, as well as traditional and procedural risk factors - are now urgently awaited in order to define the optimal therapeutic strategies and management providing the best benefit for a given individual patient.
ACCESSION #
51503636

 

Related Articles

  • The role of genetic factors in clopidogrel antiplatelet therapy. Cieślewicz, Artur Robert; Kaźmierczak, Ewa; Jabłecka, Anna // Advances in Interventional Cardiology;2012, Vol. 8 Issue 2, p126 

    Thienopyridine derivative antiplatelet agents play an important role in the treatment of coronary artery disease. Clopidogrel is a drug blocking action of the platelet ADP receptor (P2Y12). It is applied in the form of a prodrug that requires metabolic activation by cytochrome P450 enzymes. The...

  • Pharmacogenetics and Clopidogrel Response in Patients Undergoing Percutaneous Coronary Interventions. Beitelshees, A. L.; Horenstein, R. B.; Vesely, M. R.; Mehra, M. R.; Shuldiner, A. R. // Clinical Pharmacology & Therapeutics;Mar2011, Vol. 89 Issue 3, p455 

    The article focuses on the association between cytochrome P450 2C19 (CYP2C19) and clopidogrel response in patients under percutaneous coronary interventions. It says that studies from 2008 show that CYP2C19*2 genotype increase the risk of patients to have cardiovascular events but the Platelet...

  • Ticagrelor: An oral, non-thienopyridine P2Y12 receptor antagonist for the treatment of acute coronary syndromes. Jennings, Douglas L. // Formulary;May2010, Vol. 45 Issue 5, p148 

    Coronary heart disease and acute coronary syndromes (ACS) are a significant cause of morbidity and mortality in the United States. The cornerstone of ACS management is combination oral antiplatelet therapy, usually with aspirin and a thienopyridine. Clopidogrel, the most commonly used...

  • Various drugs.  // Reactions Weekly;11/21/2009, Issue 1279, p33 

    The article describes the case of a 74-year-old man who developed thrombocytopenia while under a treatment regimen composed of clopidogrel, aspirin, paracetamol/chlorphenamine/caffeine and aminophenazone. The patient was diagnosed with coronary artery disease, and underwent a surgery for a...

  • Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel. Bo Jin; Huan-Chun Ni; Wei Shen; Jian Li; Hai-Ming Shi; Yong Li // Molecular Biology Reports;Mar2011, Vol. 38 Issue 3, p1697 

    Patients with lesser degrees of platelet inhibition in response to clopidogrel appear to be at increased risk for recurrent ischemic events. Cytochrome P450 (CYP) polymorphisms have been proposed as possible mechanisms for nonresponsiveness to clopidogrel. Published data on the association...

  • Prevalence of CYP2C19 polymorphisms in the Lebanese population. Djaffar Jureidini, Isabelle; Chamseddine, Nabil; Keleshian, Sose; Naoufal, Rania; Zahed, Laila; Hakime, Noha // Molecular Biology Reports;Nov2011, Vol. 38 Issue 8, p5449 

    Clopidogrel is one of the most commonly prescribed drugs, as its combination with low-dose aspirin is the recommended oral anti-platelet therapy, to prevent ischaemic events following coronary syndromes or stent placement. Numerous recent studies have shown that polymorphisms in the gene...

  • Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance. Siasos, Gerasimos; Oikonomou, Evangelos; Vavuranakis, Manolis; Kokkou, Eleni; Mourouzis, Konstantinos; Tsalamandris, Sotiris; Zaromitidou, Marina; Kioufis, Stamatios; Tsigkou, Vasiliki; Deftereos, Spyridon; Stefanadis, Christodoulos; Tousoulis, Dimitris // Cardiology;May2017, Vol. 137 Issue 2, p104 

    Objectives: Individual platelet responses to antiplatelet therapy depend on genetic, cellular and clinical factors. CYP2C19 and P2Y12 receptor polymorphisms are implicated in platelet responses to antiplatelet treatment. We aimed to evaluate the impact of CYP2C19 and C34T P2Y12 genotyping on...

  • Clopidogrel: A Pharmacogenomic Perspective on its Use in Coronary Artery Disease. Terpening, Chris // Clinical Medicine Insights: Cardiology;2010, Issue 4, p117 

    The thienopyridine antiplatelet agent clopidogrel is an effective drug for the prevention of vascular events. However, data has accumulated over time to suggest it is prone to significant interpatient variability. While there are several factors that contribute to this, one of the most important...

  • Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy. Scott, S. A.; Sangkuhl, K.; Gardner, E. E.; Stein, C. M.; Hulot, J.-S.; Johnson, J. A.; Roden, D. M.; Klein, T. E.; Shuldiner, A. R. // Clinical Pharmacology & Therapeutics;Aug2011, Vol. 90 Issue 2, p328 

    The article discusses the implementation of consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. It mentions the aim of the guidelines which is to provide information regarding the clinical use of CYP2C19 genotype test results in patients requiring...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics